Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Vertiv | Flex | Eli Lilly and Company | |
|---|---|---|---|
| Moat rating | narrow The FY2025 10-K splits its competition into niche players (Delta, Stulz, Johnson Controls, Socomec) and large-scale globals (Schneider, Eaton, Legrand, Huawei) — real differentiation inside a field that contains several larger diversified rivals. | none The FY2026 10-K (fiscal year ended March 31, 2026) concedes the core business is contested on every side: "Our industry is extremely competitive, many of our competitors have achieved substantial market share, and some may have lower cost structures or greater design, manufacturing, financial or other resources than we do." Customers "could in the future decide to in-source, dual-source, regionalize, or otherwise reallocate manufacturing volumes among suppliers", certain contracts "permit the customer to terminate the agreement for convenience upon prior written notice", and hyperscale customers "typically have substantial purchasing power and negotiating leverage". TradingPilot's stored fundamentals (SEC XBRL) show gross profit of $1,976 million on net sales of $28,502 million in fiscal 2023 and $2,567 million on $27,914 million in fiscal 2026: a thin margin, even after widening. The Cloud and Power Infrastructure (CPI) segment sells its own power and cooling products, but the 10-K says it must keep offering "significant price and/or performance advantages over competitive products", and Flex intends to separate it into an independent company targeted for the first quarter of calendar 2027. A large contract manufacturer whose own filing describes no protected position: no moat is claimable. | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. |
| Moat type | switching costs The filing pairs installed critical infrastructure with a lifecycle service estate — preventative maintenance, project management, acceptance testing, remote monitoring, spares — across more than 40 countries; ripping out the vendor means ripping out the service relationship too. | none The 10-K's competitive strengths are operating capabilities, not a durable barrier: "Global Scale and Regional Strength" (more than 100 facilities across approximately 30 countries, staffed by approximately 150,000 employees), "Long-Standing, Diverse Customer Relationships", "Cross-Industry Synergies" and cost-efficient industrial parks. On intellectual property it says "we do not consider any single patent, trademark, or license to be material to our business as a whole" and that the carrying value of its intellectual property "was not material". Switching costs are limited by short commitments: "We generally do not obtain firm, long-term purchase commitments from our customers", and termination-for-convenience notice periods "may be relatively short". | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. |
| Leadership | co leader Named against Schneider Electric and Eaton among global competitors; the filing claims differentiation through application expertise and the most comprehensive portfolio — attributed, not independently measured. | at parity EMSNOW/in4ma's "EMS&ODM Global 100" (2026-03-06, https://www.emsnow.com/?p=53535) says Wistron, Quanta and Wiwynn "plus Foxconn together account for nearly 57% of global EMS/ODM production", and groups Flex with Jabil, Celestica and Sanmina as the US "big four", "representing about 85% of the revenue base among ~20 US headquartered EMS/ODM". The FY2026 10-K claims no rank and says "many of our competitors have achieved substantial market share". One of a handful of large Western contract manufacturers, behind the Taiwanese leaders in scale: at parity with its peer group, not a leader. | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. |
| Pricing power | moderate The filing lists price as one of five competitive bases but leads with reliability and quality, and sells into customers 'in some of the world's most critical industries' — where downtime, not price, is the binding constraint. | weak Stored fundamentals show gross profit of $1,976 million on $28,502 million of net sales in fiscal 2023 and $2,567 million on $27,914 million in fiscal 2026; on the Q1 FY2027 call (https://earningswhispers.com/transcript/FLEX/Q12027) the CFO said adjusted gross margin "improved to 9.6%, up 50 basis points from the prior year". The 10-K sets the limits: hyperscale customers have "substantial purchasing power and negotiating leverage, which they may use to obtain favorable pricing, extended payment terms, volume flexibility, or other concessions that could reduce our margins", and if CPI's competitors "adopt innovations more quickly or develop superior products, our win rates, pricing, and margins may suffer". | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. |
| Summary | Vertiv sells the power and cooling that AI compute physically cannot run without, and its filing leads with 'first-to-market designs engineered for next-gen rack-scale artificial intelligence compute.' Its customers are 'the world's most critical industries' — hyperscale, colocation, neocloud and enterprise data centers — where competition, by the filing's own account, runs on reliability, quality, price, service and customer relationships. The differentiation claims are the company's own; the breadth of the named competitor set is the check on them. | Flex designs, builds and manages products for other companies through, per its FY2026 10-K, three segments: Integrated Technology Solutions (communications, enterprise and lifestyle products), Regulated Manufacturing Solutions (industrial, automotive and healthcare) and Cloud and Power Infrastructure (integrated compute systems, liquid cooling, and utility-, facility-, rack- and board-level power). It runs more than 100 facilities in approximately 30 countries; its ten largest customers were 45% of fiscal 2026 net sales and none exceeded 10%. The data-centre business is the growth engine: on the Q1 FY2027 call (2026-07-29) the CFO said CPI revenue "totaled $2.2 billion, up 35% from the prior year, driven by strong growth in power", at a 9.7% adjusted operating margin, against 5.2% for ITS and 6.6% for RMS. Flex plans to spin CPI off as Axiom in the first quarter of calendar 2027, after funds affiliated with General Catalyst, Koch Equity Development and co-investors agreed a $2.0 billion convertible preferred investment "at an initial enterprise value for Axiom of $37.5 billion" (Flex release, 2026-10-05: https://www.sec.gov/Archives/edgar/data/866374/000119312526413173/d123485dex991.htm). The filing itself describes no durable barrier: the industry is "extremely competitive", rivals including Taiwanese ODM suppliers "in some cases, have a substantial share of global information technology hardware and related infrastructure production", customers can in-source or reallocate volume, and hyperscalers can use their leverage "to obtain favorable pricing". An independent tally (EMSNOW/in4ma, 2026-03-06) puts Foxconn, Wistron, Quanta and Wiwynn at "nearly 57% of global EMS/ODM production" and counts Flex among the US "big four". Scale plus a fast-growing power franchise that is about to leave the group, but no moat. | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." |
| Chain position | Layer-7 power and cooling under every AI rack. | Contract designer-manufacturer across many end markets and, through CPI, a supplier of power, cooling and rack-level compute infrastructure to "a limited number of hyperscale cloud providers, colocation companies, and large enterprise data center operators" (10-K), which Flex plans to separate as Axiom in the first quarter of calendar 2027. | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. |